SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
about
Comparative genomics and molecular dynamics of DNA repeats in eukaryotesEpigenetic principles and mechanisms underlying nervous system functions in health and diseaseWhere Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability DisordersRepeat-mediated genetic and epigenetic changes at the FMR1 locus in the Fragile X-related disordersSirtuins in epigenetic regulationThe promise and perils of HDAC inhibitors in neurodegenerationOpposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activityA novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome.Development of histone deacetylase inhibitors as therapeutics for neurological diseaseHistone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome.The distribution of repressive histone modifications on silenced FMR1 alleles provides clues to the mechanism of gene silencing in fragile X syndrome.The role of histone acetylation in memory formation and cognitive impairments.Transcription elongation and tissue-specific somatic CAG instability.Polycomb group complexes are recruited to reactivated FMR1 alleles in Fragile X syndrome in response to FMR1 transcriptionRepeat expansion affects both transcription initiation and elongation in friedreich ataxia cellsHigh-Throughput Screening to Identify Compounds That Increase Fragile X Mental Retardation Protein Expression in Neural Stem Cells Differentiated From Fragile X Syndrome Patient-Derived Induced Pluripotent Stem Cells.Bromodomain inhibitors regulate the C9ORF72 locus in ALSRepeat-mediated epigenetic dysregulation of the FMR1 gene in the fragile X-related disorders.Chromatin changes in the development and pathology of the Fragile X-associated disorders and Friedreich ataxia.Reactivation of FMR1 by CRISPR/Cas9-Mediated Deletion of the Expanded CGG-Repeat of the Fragile X Chromosome.Epigenetics in Friedreich's Ataxia: Challenges and Opportunities for Therapy.Genome-wide methylation analysis demonstrates that 5-aza-2-deoxycytidine treatment does not cause random DNA demethylation in fragile X syndrome cells.Epigenetics in nucleotide repeat expansion disorders.Instability and chromatin structure of expanded trinucleotide repeatsThe biological effects of simple tandem repeats: lessons from the repeat expansion diseases.Can Sir(2) regulate cancer?Sirtuin inhibitors.Sirtuin activators and inhibitors.Epigenetic-based therapies for Friedreich ataxia.Human pluripotent stem cell models of Fragile X syndrome.Sustained expression of FMR1 mRNA from reactivated fragile X syndrome alleles after treatment with small molecules that prevent trimethylation of H3K27.Genetics and Epigenetics in Adult Neurogenesis.A quantitative homogeneous assay for fragile X mental retardation 1 protein.Targeted Reactivation of Transcription in Fragile X Syndrome Embryonic Stem Cells
P2860
Q24650948-5FFFACD2-26EA-4F6A-B301-76217E49EC15Q24657549-A7B11AA9-7856-4AE3-B3DB-4246CD19A092Q26740071-34C36CC4-F6A6-432B-BE47-EE1D607AE642Q27011565-68BA715D-12D8-448A-BD94-DEC96C9150E7Q27026861-BC9313DE-0BB0-4B02-B44B-A66E64EE616BQ28087539-989FD61C-BD5B-46E7-B2E4-30BA3B128C24Q33396651-DDB0807A-FC8A-4A06-AE2A-013C379400C8Q33652584-70525172-889D-47CD-87CD-10CB3BDC0765Q33670661-CB98CE23-C3BB-4A02-AED4-2B5BD09AA5B7Q33775485-A6D95AB5-CBDC-4BB6-AA9F-9CC9451CD6A6Q34275676-885F534A-F89E-40D2-B92C-C263EA5407EEQ34279114-86DB9048-F32E-40F9-8913-1D349329181FQ34499436-0476106A-3D53-46D3-8CF2-6868B5218FA1Q34555504-5557AC20-5D22-44C8-A28B-635B3323D305Q34575655-089E6C5C-73A1-4700-82F2-F145B562B1AFQ35638949-EEE69FF7-7081-4C65-B654-33540CC6BBB6Q35670978-FE3EFC2D-911F-4F37-B899-5650277DFB37Q35675960-3E327F21-2831-4A53-8B3A-1CAF58A1F7D7Q36016607-FCA7E7FD-0173-4E4E-831D-551CA0ED20E6Q36170928-1C8E814E-6220-49ED-9C32-714252807B38Q36663928-E31E9877-1708-40EC-B3FC-6097FBD44286Q36725163-0D02FD45-3BE6-4616-B7EF-410D4EF4E50BQ36848454-63B8B51A-AB5D-48E2-8259-B6E9011849C7Q36900707-ED14B0CF-514D-4A21-8E44-B85694A56F15Q37204533-F1581E44-8452-4A5E-AD77-7F3A0534DEDFQ37340324-0CBC75B3-46F2-4E78-B57F-E34B6C98831EQ37481259-FF7D3C1B-F6B8-4D65-B6A7-3429AB8FC012Q38021431-C28E051D-FEEB-4FE1-B1A1-B537C7A8A636Q38219414-60DA9511-0787-4E27-86BE-C720831C29FCQ38660520-E6C94EEB-6C2E-4540-8C08-BCDE50742163Q38759837-9E61C7BF-007B-4B2C-BC4B-45E4BF5C1E7EQ38825010-56ECBDC3-61BE-46D0-87D5-E23126DF370FQ40099259-E7C7B039-AA58-42CE-B894-036C65A7E481Q58777280-A242B030-C1AA-4299-A6E3-F48DCDA49AC8
P2860
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
@ast
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
@en
type
label
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
@ast
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
@en
prefLabel
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
@ast
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
@en
P2093
P2860
P1433
P1476
SIRT1 inhibition alleviates gene silencing in Fragile X mental retardation syndrome
@en
P2093
Daman Kumari
Karen Usdin
Rea Biacsi
P2860
P304
P356
10.1371/JOURNAL.PGEN.1000017
P577
2008-03-07T00:00:00Z